Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer effects on lipid metabolism

Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer : effects on lipid metabolism

Twenty-four previously untreated patients with a diagnosis of prostatic cancer were treated with chlormadinone acetate (CMA) alone (100 mg/day) for 4 weeks, and luteinizing hormone-releasing hormone analogue (LH-RHa) was added for the next 24 weeks. Marked decreases in blood LH, testosterone (T), pr...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 44(1998), 7 vom: 05. Juli, Seite 525-32
1. Verfasser: Shimada, M (VerfasserIn)
Weitere Verfasser: Uchida, H, Kasahara, T, Fuji, K, Ogawa, Y, Yoshida, H, Hamajima, T, Matsuda, N, Ikeuchi, T, Kai, Y, Hiramori, M, Hoshino, M, Inoue, K, Higaki, Y
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 1998
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Clinical Trial English Abstract Journal Article Antineoplastic Agents, Hormonal Apolipoproteins Progesterone Congeners Triglycerides Chlormadinone Acetate 0SY050L61N Testosterone mehr... 3XMK78S47O Cholesterol 97C5T2UQ7J Prostate-Specific Antigen EC 3.4.21.77 Leuprolide EFY6W0M8TG
LEADER 01000naa a22002652 4500
001 NLM096912200
003 DE-627
005 20231222104836.0
007 tu
008 231222s1998 xx ||||| 00| ||jpn c
028 5 2 |a pubmed24n0323.xml 
035 |a (DE-627)NLM096912200 
035 |a (NLM)9752613 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a jpn 
100 1 |a Shimada, M  |e verfasserin  |4 aut 
245 1 0 |a Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer  |b effects on lipid metabolism 
264 1 |c 1998 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 22.10.1998 
500 |a Date Revised 21.11.2013 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Twenty-four previously untreated patients with a diagnosis of prostatic cancer were treated with chlormadinone acetate (CMA) alone (100 mg/day) for 4 weeks, and luteinizing hormone-releasing hormone analogue (LH-RHa) was added for the next 24 weeks. Marked decreases in blood LH, testosterone (T), prostate specific antigen (PSA), gamma-seminoprotein (gamma-Sm), and prostatic acid phosphatase (PAP) were observed after a single dose of CMA. T levels were significantly increased 3 days after the initial dose of LH-RHa, and did not return to the pretreatment level. There were no significant increases in any of the markers, nor were there any flare-up cases. Triglyceride levels, which were slightly elevated before the start of treatment, were significantly decreased 24 weeks after the completion of combined therapy. PSA was evaluated as partial response (PR) or better in 86.7% of the patients. Overall evaluation showed PR or better in 75.0% of the patients. These findings suggest that prior administration of CMA followed by combined administration with LH-RHa is useful in the treatment of prostatic cancer. No negative effects on lipid metabolism were observed at any time during the treatment period 
650 4 |a Clinical Trial 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a Antineoplastic Agents, Hormonal  |2 NLM 
650 7 |a Apolipoproteins  |2 NLM 
650 7 |a Progesterone Congeners  |2 NLM 
650 7 |a Triglycerides  |2 NLM 
650 7 |a Chlormadinone Acetate  |2 NLM 
650 7 |a 0SY050L61N  |2 NLM 
650 7 |a Testosterone  |2 NLM 
650 7 |a 3XMK78S47O  |2 NLM 
650 7 |a Cholesterol  |2 NLM 
650 7 |a 97C5T2UQ7J  |2 NLM 
650 7 |a Prostate-Specific Antigen  |2 NLM 
650 7 |a EC 3.4.21.77  |2 NLM 
650 7 |a Leuprolide  |2 NLM 
650 7 |a EFY6W0M8TG  |2 NLM 
700 1 |a Uchida, H  |e verfasserin  |4 aut 
700 1 |a Kasahara, T  |e verfasserin  |4 aut 
700 1 |a Fuji, K  |e verfasserin  |4 aut 
700 1 |a Ogawa, Y  |e verfasserin  |4 aut 
700 1 |a Yoshida, H  |e verfasserin  |4 aut 
700 1 |a Hamajima, T  |e verfasserin  |4 aut 
700 1 |a Matsuda, N  |e verfasserin  |4 aut 
700 1 |a Ikeuchi, T  |e verfasserin  |4 aut 
700 1 |a Kai, Y  |e verfasserin  |4 aut 
700 1 |a Hiramori, M  |e verfasserin  |4 aut 
700 1 |a Hoshino, M  |e verfasserin  |4 aut 
700 1 |a Inoue, K  |e verfasserin  |4 aut 
700 1 |a Higaki, Y  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Hinyokika kiyo. Acta urologica Japonica  |d 1962  |g 44(1998), 7 vom: 05. Juli, Seite 525-32  |w (DE-627)NLM012631779  |x 0018-1994  |7 nnns 
773 1 8 |g volume:44  |g year:1998  |g number:7  |g day:05  |g month:07  |g pages:525-32 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_350 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2003 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2006 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2010 
912 |a GBV_ILN_2012 
912 |a GBV_ILN_2018 
951 |a AR 
952 |d 44  |j 1998  |e 7  |b 05  |c 07  |h 525-32